Zoetis Inc. (NYSE:ZTS) Shares Acquired by Weaver Capital Management LLC

Weaver Capital Management LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 27.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,221 shares of the company’s stock after acquiring an additional 480 shares during the period. Weaver Capital Management LLC’s holdings in Zoetis were worth $434,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Webster Bank N. A. increased its position in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Quarry LP increased its position in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. LRI Investments LLC acquired a new stake in Zoetis in the first quarter worth $43,000. Central Valley Advisors LLC acquired a new stake in Zoetis in the second quarter worth $49,000. Finally, Future Financial Wealth Managment LLC acquired a new stake in Zoetis in the first quarter worth $51,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 0.0 %

Shares of ZTS opened at $189.52 on Wednesday. The business’s 50-day moving average price is $189.11 and its 200 day moving average price is $177.50. The stock has a market capitalization of $86.48 billion, a P/E ratio of 36.52, a P/E/G ratio of 3.00 and a beta of 0.89. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the business posted $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.91%. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.